387 related articles for article (PubMed ID: 16682686)
1. Variable benefit in neuropsychological function in HIV-infected HAART-treated patients.
Cysique LA; Maruff P; Brew BJ
Neurology; 2006 May; 66(9):1447-50. PubMed ID: 16682686
[TBL] [Abstract][Full Text] [Related]
2. The incidence of and risk factors for HIV-associated cognitive-motor complex among patients on HAART.
Jevtović Dj; Vanovac V; Veselinović M; Salemović D; Ranin J; Stefanova E
Biomed Pharmacother; 2009 Sep; 63(8):561-5. PubMed ID: 19026516
[TBL] [Abstract][Full Text] [Related]
3. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
4. HIV suppression by HAART preserves cognitive function in advanced, immune-reconstituted AIDS patients.
McCutchan JA; Wu JW; Robertson K; Koletar SL; Ellis RJ; Cohn S; Taylor M; Woods S; Heaton R; Currier J; Williams PL
AIDS; 2007 May; 21(9):1109-17. PubMed ID: 17502721
[TBL] [Abstract][Full Text] [Related]
5. Antiretroviral therapy in HIV infection: are neurologically active drugs important?
Cysique LA; Maruff P; Brew BJ
Arch Neurol; 2004 Nov; 61(11):1699-704. PubMed ID: 15534181
[TBL] [Abstract][Full Text] [Related]
6. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
[TBL] [Abstract][Full Text] [Related]
7. HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy.
Steingrover R; Pogány K; Fernandez Garcia E; Jurriaans S; Brinkman K; Schuitemaker H; Miedema F; Lange JM; Prins JM
AIDS; 2008 Aug; 22(13):1583-8. PubMed ID: 18670217
[TBL] [Abstract][Full Text] [Related]
8. Neurological disease: the effects of HIV and antiretroviral therapy and the implications for early antiretroviral therapy initiation.
Wright EJ
Curr Opin HIV AIDS; 2009 Sep; 4(5):447-52. PubMed ID: 20048710
[TBL] [Abstract][Full Text] [Related]
9. Depression and neurocognitive performance in individuals with HIV/AIDS: 2-year follow-up.
Gibbie T; Mijch A; Ellen S; Hoy J; Hutchison C; Wright E; Chua P; Judd F
HIV Med; 2006 Mar; 7(2):112-21. PubMed ID: 16420256
[TBL] [Abstract][Full Text] [Related]
10. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
11. Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa.
Sacktor N; Nakasujja N; Skolasky R; Robertson K; Wong M; Musisi S; Ronald A; Katabira E
Neurology; 2006 Jul; 67(2):311-4. PubMed ID: 16864825
[TBL] [Abstract][Full Text] [Related]
12. The HIV Dementia Scale: predictive power in mild dementia and HAART.
Bottiggi KA; Chang JJ; Schmitt FA; Avison MJ; Mootoor Y; Nath A; Berger JR
J Neurol Sci; 2007 Sep; 260(1-2):11-5. PubMed ID: 17482212
[TBL] [Abstract][Full Text] [Related]
13. Persistent brain abnormalities in antiretroviral-naive HIV patients 3 months after HAART.
Chang L; Ernst T; Witt MD; Ames N; Walot I; Jovicich J; DeSilva M; Trivedi N; Speck O; Miller EN
Antivir Ther; 2003 Feb; 8(1):17-26. PubMed ID: 12713060
[TBL] [Abstract][Full Text] [Related]
14. CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load.
Torti C; Lapadula G; Barreiro P; Soriano V; Mandalia S; De Silvestri A; Suter F; Maggiolo F; Antinori A; Antonucci F; Maserati R; El Hamad I; Pierotti P; Sighinolfi L; Migliorino G; Ladisa N; Carosi G;
J Antimicrob Chemother; 2007 Jun; 59(6):1141-7. PubMed ID: 17434879
[TBL] [Abstract][Full Text] [Related]
15. Setting a minimum threshold CD4 count for initiation of highly active antiretroviral therapy in HIV-infected patients.
Ho C; Lee S; Wong Kh; Cheng L; Lam M
HIV Med; 2007 Apr; 8(3):181-5. PubMed ID: 17461862
[TBL] [Abstract][Full Text] [Related]
16. Progression of HIV-associated dementia treated with HAART.
Dougherty RH; Skolasky RL; McArthur JC
AIDS Read; 2002 Feb; 12(2):69-74. PubMed ID: 11905143
[TBL] [Abstract][Full Text] [Related]
17. Differential impact of adherence on long-term treatment response among naive HIV-infected individuals.
Lima VD; Harrigan R; Murray M; Moore DM; Wood E; Hogg RS; Montaner JS
AIDS; 2008 Nov; 22(17):2371-80. PubMed ID: 18981777
[TBL] [Abstract][Full Text] [Related]
18. Sex differences in the clinical, immunological and virological parameters of HIV-infected patients treated with HAART.
Collazos J; Asensi V; Cartón JA
AIDS; 2007 Apr; 21(7):835-43. PubMed ID: 17415038
[TBL] [Abstract][Full Text] [Related]
19. Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Chaix ML; Desquilbet L; Descamps D; Costagliola D; Deveau C; Galimand J; Goujard C; Signori-Schmuck A; Schneider V; Tamalet C; Pellegrin I; Wirden M; Masquelier B; Brun-Vezinet F; Rouzioux C; Meyer L; ;
Antivir Ther; 2007; 12(8):1305-10. PubMed ID: 18240870
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
Li H; Zheng YH; Shen Z; Liu M; Liu C; He Y; Chen J; Ou QY; Huang ZL
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(42):2973-6. PubMed ID: 18261327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
